Last Close
Jun 17  •  12:26PM ET
6.89
Dollar change
+0.03
Percentage change
0.45
%
Index
RUT
P/E
95.97
EPS (ttm)
0.07
Insider Own
56.49%
Shs Outstand
246.42M
Perf Week
5.53%
Market Cap
1.71B
Forward P/E
5.70
EPS next Y
1.21
Insider Trans
-1.51%
Shs Float
107.85M
Perf Month
7.33%
Enterprise Value
3.34B
PEG
0.23
EPS next Q
0.19
Inst Own
41.11%
Perf Quarter
12.05%
Income
19.05M
P/S
0.58
EPS this Y
26.97%
Inst Trans
4.44%
Perf Half Y
23.94%
Sales
2.95B
P/B
2.41
EPS next Y
14.73%
ROA
0.46%
Perf YTD
40.92%
Book/sh
2.86
P/C
14.86
EPS next 5Y
24.74%
ROE
3.66%
52W High
7.52 -8.37%
Perf Year
57.69%
Cash/sh
0.46
P/FCF
6.22
EPS past 3/5Y
8.11% -35.60%
ROIC
0.81%
52W Low
4.28 61.00%
Perf 3Y
-9.21%
Dividend Est.
-
EV/EBITDA
8.91
Sales past 3/5Y
2.38% 26.71%
Gross Margin
29.92%
Volatility
4.20% 4.98%
Perf 5Y
36.45%
Dividend TTM
-
EV/Sales
1.13
EPS Y/Y TTM
868.83%
Oper. Margin
4.58%
ATR (14)
0.31
Perf 10Y
-62.08%
Dividend Ex-Date
-
Quick Ratio
0.83
Sales Y/Y TTM
4.48%
Profit Margin
0.65%
RSI (14)
57.23
Dividend Gr. 3/5Y
- -
Current Ratio
0.83
EPS Q/Q
-98.85%
SMA20
2.97%
Beta
1.27
Payout
0.00%
Debt/Eq
2.42
Sales Q/Q
7.82%
SMA50
4.35%
Rel Volume
0.85
Prev Close
6.86
Employees
12629
LT Debt/Eq
2.35
SMA200
20.56%
Avg Volume
1.44M
Price
6.89
IPO
Apr 17, 1995
Option/Short
Yes / Yes
Trades
Volume
582,783
Change
0.45%
Date Action Analyst Rating Change Price Target Change
Nov-17-25Initiated Seaport Research Partners Buy
May-09-25Downgrade The Benchmark Company Buy → Hold $9.50
Feb-21-25Upgrade Wells Fargo Equal Weight → Overweight $8 → $9
Jun-25-24Initiated Goldman Neutral $6.50
Oct-06-23Initiated Craig Hallum Buy $8
Aug-09-23Downgrade Stephens Overweight → Equal-Weight $11 → $8
Jul-24-23Downgrade Wells Fargo Overweight → Equal Weight $9 → $8
Jul-17-23Initiated Goldman Buy $12
Jun-28-23Initiated Morgan Stanley Equal-Weight $9
May-08-23Initiated Wells Fargo Overweight $9
Jun-16-26 10:25AM
Jun-15-26 03:25PM
Jun-10-26 09:45AM
Jun-09-26 10:35AM
Jun-08-26 04:05PM
03:40PM Loading…
Jun-02-26 03:40PM
Jun-01-26 09:15AM
May-29-26 10:30AM
May-28-26 09:31AM
May-18-26 10:00AM
May-17-26 01:01PM
May-14-26 04:01PM
May-13-26 12:55PM
May-12-26 10:35AM
06:00AM
09:00AM Loading…
May-11-26 09:00AM
07:25AM
May-08-26 04:05PM
May-05-26 08:30AM
May-04-26 11:00AM
May-01-26 08:30AM
Apr-30-26 07:32AM
07:15AM
Apr-29-26 10:00AM
Apr-28-26 12:15PM
09:30AM
09:00AM
Apr-27-26 09:00AM
Apr-21-26 12:01PM
11:30AM
06:30AM Loading…
06:30AM
Apr-17-26 09:01AM
Apr-15-26 12:10PM
Apr-14-26 04:10PM
09:00AM
Apr-13-26 09:00AM
Apr-10-26 09:30AM
Apr-09-26 10:00AM
Apr-06-26 09:00AM
Apr-03-26 10:00AM
Mar-30-26 03:10PM
12:45PM
Mar-24-26 10:25AM
Mar-20-26 04:05PM
Mar-18-26 08:00AM
Mar-16-26 04:31PM
Mar-10-26 05:00PM
09:00AM
09:00AM
08:05AM
07:15AM
Mar-09-26 05:35PM
11:15AM
Mar-05-26 07:45AM
Mar-04-26 01:05PM
10:00AM
Mar-02-26 10:40AM
08:30AM
Feb-27-26 09:30AM
06:00AM
Feb-26-26 08:30AM
08:15AM
Feb-24-26 09:50AM
Feb-18-26 05:00AM
03:52AM
Feb-17-26 04:05PM
11:48AM
Feb-12-26 08:58AM
Feb-09-26 12:10PM
Feb-05-26 08:00AM
Feb-04-26 10:00AM
Feb-02-26 12:35PM
Jan-29-26 08:30AM
Jan-26-26 07:30PM
Jan-22-26 09:01AM
Jan-21-26 08:00AM
Jan-20-26 10:00AM
Jan-07-26 10:01AM
08:30AM
Jan-06-26 12:00PM
Jan-05-26 08:00AM
Jan-02-26 04:05PM
03:32AM
Dec-29-25 11:42AM
Dec-26-25 12:00PM
Dec-24-25 09:40AM
Dec-22-25 08:00AM
Dec-18-25 09:49AM
Dec-15-25 08:55AM
Dec-10-25 09:01AM
07:00AM
Dec-09-25 03:01PM
12:52PM
12:00PM
Dec-08-25 10:09AM
09:40AM
05:00AM
Dec-04-25 02:23PM
Dec-03-25 07:01AM
Nov-25-25 10:16AM
Stagwell, Inc. operates as media and public relations agency. It delivers brands that connect culture-moving creativity with technology to harmonize the art and science of marketing. It operates through the following segments: Integrated Agencies Network, Brand Performance Network and Communications Network. The Integrated Agencies Network segment includes five operating segments: the Anomaly Alliance, Constellation, the Doner Partner Network, Code and Theory Network, and National Research Group. The Brand Performance Network consists of a single operating segment. BPN includes a unified media and data management structure with omnichannel media placement, creative media consulting, influencer and business-to-business marketing capabilities. The Communications Network reportable segment consists of a single operating segment, specialist network that provides advocacy, strategic corporate communications, investor relations, public relations, online fundraising and other services to both corporations and political and advocacy organizations and includes Allison, SKDK, Targeted Victory, and Consulum. The Corporate segment includes corporate office expenses. The company was founded on April 29, 2011 and is headquartered in New York, NY.
Chairman & CEOMr. Mark Jeffrey Penn
PresidentMr. Jay R. Leveton
Chief Financial OfficerMr. Ryan J. Greene
General CounselMr. Peter McElligott
Executive Vice President of FinanceMr. Frank P. Lanuto
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Penn Mark JefferyChief Executive OfficerMay 13 '26Buy5.8820,000117,60023,034,990May 13 04:15 PM
Gross Bradley J.DirectorMay 04 '26Sale6.042,163,79013,073,6198,789May 05 07:32 PM
Last Close
Jun 17  •  12:26PM ET
16.59
Dollar change
-0.10
Percentage change
-0.57
%
TBPH Theravance Biopharma Inc daily Stock Chart
Index
RUT
P/E
7.53
EPS (ttm)
2.20
Insider Own
6.39%
Shs Outstand
51.52M
Perf Week
1.37%
Market Cap
855.52M
Forward P/E
12.48
EPS next Y
1.33
Insider Trans
-0.93%
Shs Float
48.26M
Perf Month
2.06%
Enterprise Value
534.15M
PEG
-
EPS next Q
0.06
Inst Own
96.95%
Perf Quarter
19.99%
Income
114.54M
P/S
7.79
EPS this Y
14.17%
Inst Trans
-0.71%
Perf Half Y
-6.61%
Sales
109.78M
P/B
2.94
EPS next Y
-43.45%
ROA
28.08%
Perf YTD
-11.30%
Book/sh
5.64
P/C
2.17
EPS next 5Y
-
ROE
50.17%
52W High
21.03 -21.09%
Perf Year
56.56%
Cash/sh
7.66
P/FCF
3.18
EPS past 3/5Y
- -
ROIC
32.43%
52W Low
10.42 59.26%
Perf 3Y
57.00%
Dividend Est.
-
EV/EBITDA
92.25
Sales past 3/5Y
27.91% 8.38%
Gross Margin
94.81%
Volatility
1.99% 1.96%
Perf 5Y
-5.87%
Dividend TTM
-
EV/Sales
4.87
EPS Y/Y TTM
291.20%
Oper. Margin
0.08%
ATR (14)
0.36
Perf 10Y
-23.95%
Dividend Ex-Date
-
Quick Ratio
13.14
Sales Y/Y TTM
68.20%
Profit Margin
104.34%
RSI (14)
54.23
Dividend Gr. 3/5Y
- -
Current Ratio
13.14
EPS Q/Q
64.79%
SMA20
1.75%
Beta
0.18
Payout
0.00%
Debt/Eq
0.25
Sales Q/Q
15.02%
SMA50
0.53%
Rel Volume
0.48
Prev Close
16.69
Employees
90
LT Debt/Eq
0.22
SMA200
-0.19%
Avg Volume
426.54K
Price
16.59
IPO
May 16, 2014
Option/Short
Yes / Yes
Trades
Volume
98,665
Change
-0.57%
Date Action Analyst Rating Change Price Target Change
Mar-05-26Downgrade Oppenheimer Outperform → Perform
Mar-04-26Downgrade B. Riley Securities Buy → Neutral $14
Dec-03-25Initiated Oppenheimer Outperform $27
Sep-12-25Initiated B. Riley Securities Buy $28
Aug-06-24Downgrade Leerink Partners Outperform → Market Perform $15 → $10
Apr-12-24Initiated BTIG Research Buy $21
Jan-08-24Downgrade Evercore ISI Outperform → In-line
May-23-22Initiated SVB Leerink Outperform $12
Nov-05-21Upgrade JP Morgan Underweight → Neutral $12
Sep-15-21Downgrade JP Morgan Overweight → Underweight $7
May-07-26 08:39AM
08:30AM
Mar-19-26 08:37AM
08:30AM
Mar-18-26 10:00AM
09:35AM Loading…
Mar-09-26 09:35AM
Mar-06-26 09:35AM
Mar-04-26 10:34AM
07:32AM
Mar-03-26 04:18PM
01:19PM
11:05AM
08:30AM
Feb-24-26 08:02AM
Jan-28-26 01:15PM
09:50AM Loading…
Jan-23-26 09:50AM
Jan-15-26 09:45AM
Jan-06-26 09:50AM
Dec-24-25 09:45AM
Dec-22-25 09:55AM
Dec-10-25 11:30AM
Dec-08-25 12:00PM
09:50AM
Dec-05-25 09:55AM
09:45AM
Nov-20-25 11:00AM
09:50AM
Nov-19-25 09:45AM
06:00AM
Nov-11-25 02:14PM
10:10AM Loading…
10:10AM
12:04AM
Nov-10-25 05:20PM
04:20PM
04:05PM
Nov-06-25 09:15AM
Oct-30-25 02:05PM
Oct-29-25 06:00AM
Oct-27-25 06:00AM
Oct-16-25 08:05AM
Oct-14-25 06:00AM
Sep-11-25 11:30AM
Sep-02-25 06:00AM
Aug-25-25 06:00AM
Aug-13-25 12:31PM
03:14AM
Aug-12-25 05:25PM
04:23PM
04:05PM
Aug-11-25 09:29AM
Aug-07-25 08:25AM
Jul-28-25 06:00AM
Jul-23-25 06:00AM
Jul-17-25 09:11AM
Jul-16-25 09:01AM
Jul-15-25 08:59AM
Jun-27-25 07:36AM
Jun-26-25 06:00AM
Jun-03-25 11:53AM
Jun-02-25 06:00AM
May-13-25 06:00AM
May-09-25 12:39PM
12:00PM
03:47AM
May-08-25 06:05PM
04:05PM
May-07-25 10:52AM
May-06-25 05:30PM
Apr-28-25 06:00AM
Apr-24-25 06:00AM
Apr-07-25 03:55PM
Mar-31-25 06:00AM
Mar-28-25 11:30AM
Mar-27-25 06:00AM
Feb-27-25 02:26AM
Feb-26-25 05:15PM
04:05PM
Feb-25-25 10:55AM
Feb-20-25 06:00AM
Feb-12-25 06:00AM
Feb-05-25 06:00AM
Jan-27-25 03:57AM
Jan-18-25 08:20AM
Dec-19-24 08:00AM
Dec-17-24 06:00AM
Dec-12-24 11:30AM
Nov-20-24 06:00AM
Nov-13-24 02:22AM
Nov-12-24 06:05PM
04:05PM
Nov-11-24 07:16AM
Oct-24-24 06:00AM
Oct-18-24 09:00AM
Sep-10-24 11:01AM
Sep-04-24 11:30AM
Aug-27-24 06:00AM
Aug-14-24 05:03PM
Aug-06-24 10:56AM
Aug-05-24 06:00PM
04:05PM
Theravance Biopharma, Inc. is a biopharmaceutical company, which engages in the discovery, research, development, and commercialization of respiratory medicines. It operates through the following geographical segments: U.S. and Europe. The company was founded in July 2013 and is headquartered in South San Francisco, CA.
CEO & DirectorMr. Rick E. Winningham M.B.A.
Chief Business Officer and Senior VP of Commercial & Medical AffairsMs. Rhonda F. Farnum
Senior VP of Development & Head of Ireland OfficeDr. Aine Miller Ph.D.
Senior VP & CFOMr. Aziz Sawaf C.F.A.
Senior VP of IT&I and Chief Information OfficerMr. Stuart Knight
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
RHONDA FARNUMOfficerJun 15 '26Proposed Sale16.3913,314218,167Jun 15 05:25 PM
Farnum RhondaSVP, COMM & MEDICAL AFFAIRSMar 16 '26Sale13.9631,067433,637232,699Mar 18 06:12 PM
RHONDA FARNUMOfficerMar 16 '26Proposed Sale13.9631,067433,637Mar 16 04:17 PM
Farnum RhondaSVP, COMM & MEDICAL AFFAIRSDec 03 '25Sale18.7531,067582,501277,695Dec 05 06:02 PM
RHONDA FARNUMOfficerDec 03 '25Proposed Sale18.7531,067582,500Dec 03 04:19 PM
ERAN BROSHYDirectorNov 26 '25Proposed Sale20.0029,501590,020Nov 26 04:02 PM
ERAN BROSHYDirectorNov 11 '25Proposed Sale17.9845,000809,250Nov 12 09:02 AM
Farnum RhondaSVP, COMM & MEDICAL AFFAIRSJul 14 '25Sale11.3910,000113,870326,918Jul 16 06:01 PM
RHONDA FARNUMOfficerJul 14 '25Proposed Sale11.3910,000113,869Jul 14 04:03 PM